Sanofi has turned over to Evotec its infectious disease pipeline, which consists of more than 10 undisclosed early-stage preclinical assets. Under the terms of the deal, Evotec will get $73.9 million upfront and will lead the research and development on the portfolio while Sanofi will retain undisclosed advancement, manufacturing and marketing option rights to the assets it contributes.
Evotec to lead Sanofi's infectious disease pipeline development
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.